Setting new standards in information exchange for the pharmaceutical and biotech industry
IO 360° Speaker RJ Motzer and BMS Featured in Article on FDA Granting Priority Review to Nivolumab for Renal Cell Carcinoma
November 19, 2015
Congratulations to BMS on receiving priority review for Opdivo in renal cell carcinoma. Final approval for the application will be made by March 16, 2016.
“Nivolumab showed a favorable toxicity profile, with fewer grade 3 or 4 adverse events compared to everolimus. One of the previous standouts for everolimus as a popular treatment in kidney cancer was its favorable safety profile, so showing an improvement in the safety profile compared to everolimus is really remarkable.”
Dr. Motzer will be delivering an in depth talk on the most current phase III data for Nivolumab for Renal Cell Carcinoma at the 2nd Annual Immuno-Oncology 360° conference taking place February 2-3, 2016 at The New York Academy of Medicine, NYC
To read the full article visit: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-nivolumab-for-renal-cell-carcinoma
For more information on the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/